Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Abstract: A pharmaceutical composition comprising a polymeric binder including a high molecular weight synthetic polymer having a backbone constituted of non hydrolysable covalent bonds, said polymer being able to form electrostatic bonds at a pH lower than the isoelectric point of gluten and peptides derived from the degradation of gluten, and being able to bind to gluten or peptides derived from the degradation of gluten in the gastrointestinal tract, and a pharmaceutically acceptable carrier. Methods of using the polymeric binder for binding gluten or a peptide derived from the degradation of gluten, for decreasing the degradation of gluten into toxic peptides or for decreasing interaction of gluten or peptides derived from the degradation of gluten with the gastrointestinal mucosa.

Abstract: A system and method are provided for securing an ingestible electronic device to a pharmaceutical product without damaging the ingestible electronic device. The product includes the ingestible electronic device being placed on the product in accordance with one aspect of the present invention. In accordance with another aspect of the present invention, the ingestible electronic device is placed inside the product. Various embodiments are disclosed in accordance with the present invention for protecting and/or coating of the electronic marker as well as securing the ingestible electronic device onto the product.

Abstract: The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals.

Abstract: The invention provides methods for treatment of conditions which require phytosterol therapy without adversely affecting the bioavailability of lipophilic vitamins or lipophilic drugs. The method includes administering a mixture of phytosterol ester(s) (PS-E) and 1,3-diglyceride(s) (DAG) dissolved in an edible oil or fat. The invention also provides a method of improving weight management and a method of treating metabolic conditions that result in overweight. Dietary nutrients, food supplements and food articles containing the mixture are also provided.

Abstract: Embodiments of the invention generally relate to methods and supplements for increasing sex steroids and human growth hormone in a human being.

Abstract: A manufactured system for storage and delivery of an edible or potable substance is claimed.

Abstract: The present invention relates to particulate UV protection agents which are obtainable by hydrothermal treatment of a particulate metal oxide and subsequent application of a manganese oxide coating, and to the preparation and use thereof. The present invention furthermore relates to novel compositions, in particular for topical application, which are intended, in particular, for light protection of the skin and/or hair against UV radiation and free-radical-induced stress, and to the use thereof in the above-mentioned cosmetic application.

Abstract: A stable dispersion of insoluble collagen is provided by a microfluidization process. The dispersions of insoluble collagen protein remain in stable suspension under long term storage conditions, with minimal or no settling or precipitation. More specifically the invention provides a stable dispersion of insoluble collagen comprising collagen particles wherein 50% by volume of said particles are less than 30 micrometers in width. These dispersions provide collagen in an aqueous form, which enables ease of incorporation into food and beverages and ease of administration to people or other mammals in need of collagen.

Abstract: The present invention relates to a nutrient composition which contains at least a carbohydrate, a lipid, a protein, and a mineral, and is liquid or semisolid, characterized in that the volume-based median size (d50) of particles in the nutrient composition is 5 to 100 ?m and water-insoluble particles having a protein insolubilized by a divalent cation are contained as a major component of the nutrient composition, or a nutrient composition which contains at least a carbohydrate, a lipid, a protein, and a mineral, and is liquid or semisolid, characterized in that water-insoluble particles having a protein insolubilized by a divalent cation are contained as a major component of the nutrient composition and the mass of the protein with respect to the total moles of divalent ions forming the water-insoluble particles is 1.5 to 3 g/mmol.

Abstract: A method of improving health in a canine includes administering to the canine a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland of the canines to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, Oxo-proline, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.

Abstract: Embodiments of the invention generally relate to methods and supplements for increasing sex steroids and human growth hormone in a human being.

Abstract: Embodiments of the invention generally relate to methods and supplements for improving the health of human beings.

Abstract: Schistosomiasis mansoni is caused by flukes called Schistosoma(es) that enters the human body through the skin in Schistosoma infested waters. The Schistosomes travel from the skin into human blood vessels where they mate, produce antigen containing eggs that travel from the blood vessels into the small intestines, where they are released in the human feces. Male and female Schistosome mates in human blood vessels, male Schistosomes secrete a protein called TGR ? protein to the Trk receptor sites on the females Schistosomes membranes. The process stimulates the formation of chemical SmInAct in female Schistosomes, a chemical necessary for the female Schistosomes to produce eggs. This novel technique describes new methods to inhibit Trk receptor sites on female Schistosome membranes using Trk inhibitor agent to prevent TGR ? proteins from binding to the Trk receptor sites. Thus, preventing SmInAct from being created in female Schistosomes, preventing production of eggs and Schistosomiasis.

Abstract: Embodiments of the invention generally relate to methods and supplements for increasing human growth hormone (hGH) levels in healthy human beings.

Abstract: A device which facilitates the absorption of nicotine in order to reduce the incidence of tobacco smoking is disclosed. The device includes a tube defining an interior space. The tube has a first end with an opening and a second end. An inhalable, flowable liquid or gel composition is disposed in the interior space of the tube. The composition may include water, at least one vitamin, a flavoring agent, and nicotine. The flavoring agent may include an intense sweetener such as sucralose, and a natural or artificial fruit flavor. A user inhales on the first end of the tube of the device as a substitute oral activity to tobacco smoking and thereby ingests a source of nicotine that reduces the withdrawal symptoms experienced when smoking is stopped.

Abstract: The present invention provides for safe and reliable electronic circuitry that can be employed in ingestible compositions. The ingestible circuitry of the invention includes a solid support; a conductive element; and an electronic component. Each of the support, conductive element and electronic component are fabricated from an ingestible material. The ingestible circuitry finds use in a variety of different applications, including as components of ingestible identifiers, such as may be found in ingestible event markers, e.g., pharma-informatics enabled pharmaceutical compositions.

Abstract: The present invention provides, compositions, devices, and methods for affecting, among other things, weight loss and/or weight control, by sequestering nutrients or other compounds such as toxins from absorption in the digestive tract. The compositions, devices, and methods employ one or more members made of a compressible, absorbent matrix material. In various embodiments, the matrix material is suitable for routine use. The compressible absorbent matrix material has a size, shape and/or geometry configured for efficient packing into a small space, and/or configured to absorb and substantially retain digested material in the stomach. The devices and compositions may further comprise one or more hydrogel(s), soluble or insoluble fibers, waxes and/or gums to provide the desired mechanical properties and/or absorptive or shielding properties.

Abstract: Embodiments of the invention generally relate to methods and supplements for increasing human growth hormone (hGH) levels in healthy human beings.

Abstract: Bakery products and pasta with added chitosan are disclosed. The chitosan is addified with a biologically acceptable acid and added to pasta and baked products. Once the baked products and/or pasta are ingested, gastro-intestinal absorption of fats is limited even after cooking.

Abstract: A method of improving health in an animal includes administering to the animal a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland in the animal to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.

Abstract: Embodiments of the invention generally relate to supplements for increasing human growth hormone (hGH) levels in healthy human beings.

Abstract: A consumable film adapted to adhere and to dissolve in the oral cavity that provides a local anesthetic and therapeutic agents for the treatment of oral burns or injuries. The film is designed to instantly release benzocaine, or other types of local anesthetic or therapeutic agent, upon adhesion to the affected areas of the mouth, and will continue to release sufficient quantities for pain relief and for healing over an extended period of time.

Abstract: The present invention describes an orally administered edible product designed to provide a health benefit in a delivery formulation that will increase ease of use and thus lead to increased compliance and consumption to promote human health and wellness. The present invention provides an enhanced oral delivery method by developing edible products that can be ingested like food, are designed to taste like food not medicine, provide optimal absorption of lipophilic ingredients and allow for the delivery of the equivalent of multiple capsules in a single oral “dose” thus providing a superior method for the consumption of plant-based products.

Abstract: Disclosed are newborn infant formulas comprising fat, carbohydrate, and from 0.5 to 2.5 g of protein per 100 ml of formula, wherein the formula has a caloric density of from 25 to 50 kcal per 100 ml of formula. Also disclosed are methods of administering the infant formulas to provide newborns with optimal nutrition, to reduce the occurrence or extent of insulin resistance in an individual later in life, to reduce the occurrence or extent of atherosclerosis or coronary artery disease in an individual later in life, or combinations thereof, by feeding newborn infants the newborn infant formula described herein.

Abstract: The present invention relates to a method for improving the composition of the intestinal flora, to a food comprising a sphingolipid for use in such a method, to methods for the preparation of such a food and to the use of sphingolipids for the preparation of a medicine for improving the composition of the intestinal flora. More in particular, the present invention relates to a method and food in which a sphingolipid chosen from the group consisting of phytosphingosine, sphingosine, lysosphingomyelin and sphinganine, or a precursor, a derivative, or suitable salt thereof is used.

Abstract: A method for regulating glucose release, promoting glycogen conservation, and/or glycogen synthesis includes orally administering an effective amount of a nutritional composition comprising fast and slow absorbing carbohydrates in combination with an insulinomimetic compound to provide a steady release of glucose from the gastrointestinal tract.

Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.

Abstract: An edible sticker including an edible paper, an edible ink, and an edible compound on at least a portion of the edible paper. The edible compound includes one selected from a nutrient, a supplement, a medicine, a mineral, a flavoring, a vitamin, and combinations thereof. A method of providing nutrients to a child using the edible sticker, a method of manufacturing the edible sticker, and a system for manufacturing the edible sticker have also been disclosed.

Abstract: The present invention relates generally to a method of improving the antioxidant status of an infant. More particularly, the present invention relates to a method of improving the antioxidant status of an infant by administering a mixture of natural tocopherols. The natural tocopherol mixture is an effective blend of ?- and ?-tocopherol. For ease of administration and improved taste, the mixture of natural tocopherols are typically delivered in vehicle which may be in the form, for example, of a tablet, capsule, liquid, and nutritional formula. The present invention also relates to a method of improving the antioxidant status of an infant by supplementing the lactating woman wherein the supplemented breast milk is fed to the infant. Additionally, the present invention relates to a method of improving the antioxidant status of a newborn infant by supplementing the pregnant woman.

Abstract: There is provided a method for altering the distribution of body mass by altering the distribution of body mass by decreasing overall percentage fat and/or increasing the proportion of lean mass to fat mass comprising administering to a subject one or more compounds having the ability to alter body mass composition and/or ACE inhibiting activity or a physiologically acceptable derivative or prodrug thereof.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to increase bone mineral content and/or bone mass density.

Abstract: The invention relates to hydroxyflavanones, their salts and stereoisomers and their mixtures for suppressing or reducing the bitter and/or metallic taste impression. In addition, the invention relates to nutritional, nutritive or consumable preparations or oral pharmaceutical compositions, characterized in that these have an active content of hydroxyflavanones, their salts and stereoisomers or their mixtures.

Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film.

Abstract: A chewing gum with a liquid-fill composition and a surrounding gum region, with one or both containing active ingredients, such as herbal, medicinal and/or mineral elements or combinations thereof, present in an amount of at least about 0.05 mg.

Abstract: A method of orally administering jojoba for fat reduction, blood lipid reduction, and cancer prevention and treatment in humans is disclosed. The method incorporates a sufficient quantity of jojoba, defatted jojoba meal, jojoba extract, defatted jojoba meal extract, naturally derived or synthesized simmondsin, or any naturally derived or synthesized simmondsin derivative or analogue, including aglycon, or any mixture thereof into an individual's diet in the form of a food, dietary supplement, or drug to provide simmondsin component in an amount greater than 0.01% of one's total daily diet by weight, or 0.05 gram/day. The dosage amount and duration of the administration can vary to achieve and maintain one's desired body composition and blood lipid levels. The dosage and duration of administration are increased for cancer prevention and treatment.

Abstract: Methods and compositions for effectively lowering the carbon-14 content, particularly of DNA and histones in vertebrates, especially humans, to significantly below normal background levels and thereby reduce chromosomal damage using nutritional or dietary supplements based on low radiocarbon DNA, amino acid and histone precursors, further preferably including those which contribute the largest share of histone carbon atoms. Administration of the supplements during the earliest and/or most active growth stages of life is particularly beneficial. Particularly useful supplements are prepared by combining low radiocarbon precursor compounds with ordinary supplement or dietary components that exhibit substantially normal background radiocarbon concentrations.

Abstract: The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula: wherein G represents a galloyl group; theasinensins represented by the formula: wherein R1 represents G or H, and R2 represents G; and theaflavins represented by the formula: wherein R1 and R2 independently represent G or H; as well as foods and beverages and medicines containing said lipase inhibitors.

Abstract: Disclosed are compositions and corresponding methods for treating fibrocystic breast disease or other breast-related disease or condition. The compositions comprise, per serving or dose, from zero to about 400 ?g selenium, from about 100 mg to about 6000 mg gamma linolenic acid, and about 0.15 mg to about 5 mg iodine, with nutritional embodiments further comprising one or more of protein, fat, carbohydrate, vitamins, and minerals and providing from about 50 to about 1000 kcal of energy per severing or dose. Also disclosed are in-vitro studies showing that certain combinations of gamma linolenic acid, iodine, and/or selenium may 1) inhibit breast cancer or fibrocystic cell proliferation, 2) reinforce the function of tight junctions of endothelial cells and of mammary epithelial cells in estrogen-sensitive conditions, and 3) reduce the risk of vascular invasion by breast cancer cells.

Abstract: A device which facilitates the absorption of nicotine in order to reduce the incidence of tobacco smoking is disclosed. The device includes a tube defining an interior space. The tube has a first end with an opening and a second end. An inhalable, flowable liquid or gel composition is disposed in the interior space of the tube. The composition may include water, at least one vitamin, a flavoring agent, and nicotine. The flavoring agent may include an intense sweetener such as sucralose, and a natural or artificial fruit flavor. A user inhales on the first end of the tube of the device as a substitute oral activity to tobacco smoking and thereby ingests a source of nicotine that reduces the withdrawal symptoms experienced when smoking is stopped.

Abstract: A chewing gum comprising at least one active pharmaceutical ingredient (API) with a core onto which is applied at least one inner polymer film coating and thereafter onto which is applied at least one outer hard coating. A preferred API is nicotine. Flavoring agents may be incorporated in the core, in the at least one inner polymer film coating and/or in the at least one outer hard coating. The gums formed exhibit a long lasting effect of flavoring agent(s) and result in the domination of flavoring agents in the coating(s) over flavoring agent(s) in the core, thereby (a) avoiding problems of chemical or pharmaceutical incompatibility between an API in the core and flavoring agent(s) in the coating(s) and (b) achieving an increased control of the release of the API and of non-active excipients.

Abstract: The present invention relates to a nutrient composition which contains at least a carbohydrate, a lipid, a protein, and a mineral, and is liquid or semisolid, characterized in that the volume-based median size (d50) of particles in the nutrient composition is 5 to 100 ?m and water-insoluble particles having a protein insolubilized by a divalent cation are contained as a major component of the nutrient composition, or a nutrient composition which contains at least a carbohydrate, a lipid, a protein, and a mineral, and is liquid or semisolid, characterized in that water-insoluble particles having a protein insolubilized by a divalent cation are contained as a major component of the nutrient composition and the mass of the protein with respect to the total moles of divalent ions forming the water-insoluble particles is 1.5 to 3 g/mmol.

Abstract: Dietary formulations in the form of an oil emulsion providing total enteral or parenteral nutrition, or in the form of food oil suitable for oral administration is provided. The formulations include about 2-60% by calories of a C20 or longer omega-3 fatty acid and about 0.05% to 1% by calories of arachidonic acid, where the formulation provides less than 1% of total calories from linoleic acid and alpha-linolenic acid, and where the fatty acids provide 5-60% of the total calories of said dietary formulation. Methods for treatment of diseases and disorders using the dietary formulations are also provided.

Abstract: Described is the use of isoamyl acetate in food compositions for weight management and/or weight control. Further described is a beverage containing isoamyl acetate.

Abstract: This invention is concerned with the use of date syrup used as a binder (agglutinant) for solid dosage forms, such as tablets. The features of the granules and the tablets have been studied in comparison with granules and tablets which use different types of agglutinants such as starch paste and sucrose syrup and the results have shown that the use of date syrup as a binder for tablets yields results superior to other kinds of binders. In addition, date syrups gives the granules and tablets a fair color, good taste, distinct and pleasant odor, and it is favorable in regards to shape and taste by patients.

Abstract: Liquid activated infusion packet(s)/system, promoting hydration, containing active and/or inactive ingredients and/or a support member(s). Infusion Packet(s)/System is one or more individual compartments, and/or group(s), whereby the enveloping material(s) may be totally or partially dissolvable, edible, transparent, opaque, decorated, etc. Further, including of one or more: color(s), flavor(s), aroma(s), pharmaceutical(s), nutraceutical(s), dietary supplement(s), enzyme(s), pre/pro-biotic(s), amino-acid(s), soluble-fiber(s), diagnostic agent(s) etc. regardless of form, +/?effervescence, +/?uniform/controlled-release encapsulations into liquid for humans and/or animals. Enveloping material may be in whole and/or in combination; non-synthetic/porous, and/or synthetic porous/non-porous with deliberate perforations. Infusion Packet(s)/System+/?tag, support member for assistance, consumer compliance: promotion, advertising: education, entertainment, (toy/game), etc.

Abstract: A simple cellulose sulphate based microencapsulation technology has been applied to encapsulate bacterial or other microbial cells, which produce and release digestive enzymes and thereby provides an acid resistant shelter for these microbial cells. Surprisingly, the resulting spheres were found to provide sufficient protection for encapsulated cells from treatment with aqueous acidic solutions. Thereby the cellulose sulphate microencapsulated cells, such as probiotics are now enabled to survive passage, for example, through the stomach after consumption by a human or animal with a higher survival rate than those not within a microcapsule. After passing the stomach these cells are delivering products produced by them, e.g. enzymes or other nutrition factors. This technology therefore proves to be very useful in providing digestive or otherwise beneficial enzymes and/or of living microbial cells, into the lower gastrointestinal tract, where they could confer their health benefit to the host.

Abstract: Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.

Abstract: The invention is directed to microcapsules, pharmaceutical or nutraceutical compositions comprising same, and methods for preparing and using same for delivery of nanoparticle coated emulsions comprising biologically active ingredients. The microcapsule comprises barley protein, oil, and a biologically active ingredient. The microcapsule is degradable to generate a nanoparticle comprising an oil droplet coated with a barley protein.

Abstract: The present subject matter relates to palatable beverages and compositions such as non-chocolate flavored water soluble dry powder compositions comprising a cocoa extract which comprises cocoa polyphenols, and an edible acid. The present subject matter further relates to processes for formulating said beverages and compositions.